The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61. It reported earnings in this window, a natural checkpoint for the thesis.
Bio-Techne
TECH · a US exchange · USD · Market cap $11.4B · 3,100 employees
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
PASS · Titan Ethical · score 85.3Price as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price72.80 USD at the 13 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 13 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenPasses, score 85.3 out of 100
- OptionsOpen interest leans heavily to calls (put/call 0.03)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $45.00 to $71.23, base estimate $61.94 (screen dated 2026-11-13).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.03, read 2026-11-15
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Bio-Techne holds its Accumulation at $72.80. Consolidating, no directional conviction, held for 74 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 74 days |
| Price at the screen | $72.80 |
| Valuation | 66.79 trailing · 31.48 forward price to earnings |
| Values screen | PASS · score 85.3 |
| Beta | 1.28 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 17.36% | Below 33% | Interest-bearing debt is just 17.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 9.81% | Below 33% | Cash held in interest-bearing accounts and securities is 9.8% of assets, under the one-third limit. | Pass |
| Receivables | 14.43% | Below 49% | Money owed to the company is 14.4% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.32% | Below 5% | Only 0.3% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Bio-Techne clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 17%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TECH's ethical verdict changes
Today TECH passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our $61.94 fair value estimate, narrow competitive moat, 4.60% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 17.5% above the base estimate.
Third-party analyst targets: 10 covering, consensus Hold. The average target sits +0% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere our models see it going: fair-value estimate $61.94, with a range of $45.00 to $71.23, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsLab tools priced far above their growth
Picture a supplier to drug researchers whose sales are shrinking yet still trades at a 35 times forward earnings multiple. Bio-Techne sits there right now, with revenue down 2 percent, a 9 percent profit margin and just 5 percent return on equity. Our fair value sits at 59 dollars against the current 72 dollar price, leaving an 18 percent negative margin of safety and an overvalued call.
The narrow moat and hold rating from twelve analysts at a 73 dollar median target do not change the arithmetic. Ethical screens clear, yet the valuation leaves no room for the flat or falling top line the numbers already show.
Cyclical demand in research budgets can turn quickly, and a narrow moat offers little protection when growth stays negative. The gap between price and fair value remains the clearest signal.
Analysis, not advice.
| Forward P/E | 31.5xexpensive even after accounting for its growth |
| Trailing P/E | 66.8xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 1.09 |
| EPS, forward | 2.31 |
| Revenue growth | +4.6%slow but positive growth |
| Profit margin | 14.0%thin but positive margins |
| Return on equity | 8.3%a modest return on shareholder capital |
| FCF yield | 2.43% |
| Dividend yield | 0.66% |
| Debt to equity | 0.13minimal debt: a conservative balance sheet |
| Current ratio | 2.28comfortably covers its short-term bills |
| Beta | 1.28moves a little more than the market |
| Short interest, float | 0.05% |
| 52-week range | 43.20 - 72.88 |
| Moat | NARROW |
| Market cap | $11.4B |
| Employees | 3,100 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeTECH trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates Yahoo Finance · 4d ago
- Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue Estimates Yahoo Finance · 6d ago
- TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances Yahoo Finance · 7d ago
- Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates Yahoo Finance · 7d ago
- Bio-Techne (TECH), What Is Behind The Fresh Attention Now? Yahoo Finance · 11d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-08 | HERR AMY E. | Director | 6,636 | $315,874 | |
| 2026-05-08 | HERR AMY E. | Director | 6,636 | $320,386 | |
| 2026-05-05 | HIPPEL JAMES | Chief Financial Officer | 62,000 | $2,951,200 | |
| 2026-05-05 | KELDERMAN KIM | Chief Executive Officer | 26,692 | $1,270,539 | |
| 2026-05-05 | BOHNEN SHANE | General Counsel | 8,400 | $399,840 | |
| 2026-05-01 | CROUSE STEVEN C. | Officer | 794 | · | |
| 2026-04-22 | HIPPEL JAMES | Chief Financial Officer | 62,000 | · | |
| 2026-04-22 | KELDERMAN KIM | Chief Executive Officer | 11,344 | · | |
| 2026-04-14 | KELDERMAN KIM | Chief Executive Officer | 36,500 | $1,737,400 | |
| 2026-04-02 | BOHNEN SHANE | General Counsel | 2,259 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-10-28 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-10-28 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-10-28 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-10-27 | Gil Cisneros | Democrat | buy | 1K–15K |
| 2026-10-23 | Kevin Hern | Republican | sell | 15K–50K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $47.33 | +10.9% | $0.08 | $1,111 | +11.1% |
| 2 months | $55.44 | -5.3% | $0.08 | $948 | -5.2% |
| 3 months | $51.37 | +2.2% | $0.08 | $1,023 | +2.3% |
| 6 months | $60.07 | -12.6% | $0.16 | $877 | -12.3% |
| 1 year | $51.09 | +2.8% | $0.32 | $1,034 | +3.4% |
| 2 years | $76.26 | -31.2% | $0.64 | $697 | -30.3% |
| 3 years | $77.22 | -32.0% | $0.96 | $692 | -30.8% |
| 5 years | $108.52 | -51.6% | $1.60 | $499 | -50.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever TECH does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.